KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Current Leases (2021 - 2025)

Bionano Genomics' Current Leases history spans 5 years, with the latest figure at $251000.0 for Q3 2025.

  • For Q3 2025, Current Leases fell 87.17% year-over-year to $251000.0; the TTM value through Sep 2025 reached $251000.0, down 87.17%, while the annual FY2024 figure was $260000.0, 87.98% down from the prior year.
  • Current Leases for Q3 2025 was $251000.0 at Bionano Genomics, down from $1.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.2 million in Q1 2023 and bottomed at $251000.0 in Q3 2025.
  • The 5-year median for Current Leases is $1.5 million (2025), against an average of $1.2 million.
  • The largest annual shift saw Current Leases surged 658.95% in 2023 before it crashed 87.98% in 2024.
  • A 5-year view of Current Leases shows it stood at $299000.0 in 2021, then dropped by 4.68% to $285000.0 in 2022, then soared by 658.95% to $2.2 million in 2023, then plummeted by 87.98% to $260000.0 in 2024, then decreased by 3.46% to $251000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Current Leases are $251000.0 (Q3 2025), $1.3 million (Q2 2025), and $1.6 million (Q1 2025).